# A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

> **NCT06736990** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Calluna Pharma AS** · enrollment: 150 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** CAL101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06736990
- **Lead sponsor:** Calluna Pharma AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2026-11
- **Final completion:** 2027-02
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06736990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06736990, "A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06736990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*